scholarly journals P7‐43: The impact of fungal sensitization on clinical features in asthma and chronic pulmonary obstructive disease

Respirology ◽  
2021 ◽  
Vol 26 (S3) ◽  
pp. 275-275
Author(s):  
Luís Lázaro Ferreira ◽  
Nicole Fernandes ◽  
Carla Nogueira ◽  
Daniela Ferreira ◽  
Sara Conde ◽  
...  

Author(s):  
Ana Rebollo-Giménez ◽  
Lina Martínez-Estupiñán ◽  
Otto Olivas-Vergara ◽  
Gema Fuensalida-Novo ◽  
Jesús Garrido ◽  
...  

Abstract Background Digital subcutaneous tissue (SCT) changes are involved in dactylitis, a hallmark feature of psoriatic arthritis (PsA). There are no studies on the ultrasound (US) characteristics of the digital SCT in the general population. Objectives To investigate the variability in US-measured thickness (TH) and color Doppler (CD)-detected blood flow of the SCT of the volar aspects of the fingers in a non-psoriatic population and to investigate the impact of the scanning method and demographics and clinical features on these measurements. Methods SCT TH and semiquantitative (SQD) and quantitative (QD) Doppler signals were measured in the bilateral second finger at the proximal and middle phalanges in 81 non-psoriatic volunteers [49 female, 32 men; 18–78 years]. Two scanning methods with and without (thick gel layer interposition) probe-skin contact were used. Demographics and clinical features were collected. Results There was high variability of SCT TH and Doppler measurements between individuals. All US measurements obtained without probe-skin contact were significantly greater than their corresponding measurements obtained with the probe contacting the skin (p < 0.001). SCT TH was positively related to dominant hand, age, masculine gender, weight, height, body mass index, and alcohol consumption while Doppler measurements were positively related to age and non-dominant hand. Conclusions US-measured SCT thickness and Doppler-detected SCT blood flow of the volar aspect of the fingers seem to be highly variable in the non-psoriatic population as well as highly dependent on the US scanning method. This variability is of utmost importance for assessing dactylitis in PsA.


2012 ◽  
Vol 35 (11) ◽  
pp. E6-E13 ◽  
Author(s):  
Bong Gun Song ◽  
Hyun Suk Yang ◽  
Hweung Kon Hwang ◽  
Gu Hyun Kang ◽  
Yong Hwan Park ◽  
...  

2000 ◽  
Vol 18 (1) ◽  
pp. 214-214 ◽  
Author(s):  
Meletios A. Dimopoulos ◽  
Panayiotis Panayiotidis ◽  
Lia A. Moulopoulos ◽  
Petros Sfikakis ◽  
Marinos Dalakas

PURPOSE: To review the clinical features, complications, and treatment of Waldenström’s macroglobulinemia, a low-grade lymphoproliferative disorder that produces monoclonal immunoglobulin (Ig) M. METHODS: A review of published reports was facilitated by the use of a MEDLINE computer search and by manual search of the Index Medicus. RESULTS: The clinical manifestations associated with Waldenström’s macroglobulinemia can be classified according to those related to direct tumor infiltration, to the amount and specific properties of circulating IgM, and to the deposition of IgM in various tissues. Asymptomatic patients should be followed without treatment. For symptomatic patients, standard treatment consists primarily of oral chlorambucil; nucleoside analogs, such as fludarabine and cladribine, are effective in one third of previously treated patients and in up to 80% of previously untreated patients. Preliminary evidence suggests that anti-CD20 monoclonal antibody may be active in about 30% of previously treated patients and that high-dose therapy with autologous stem-cell rescue is effective in most patients, including some with resistance to nucleoside analogs. CONCLUSION: Waldenström’s macroglobulinemia has a wide clinical spectrum that practicing physicians need to recognize early to reach the correct diagnosis. When therapy is indicated, oral chlorambucil is the standard primary treatment, but cladribine or fludarabine can be used when a rapid cytoreduction is desirable. Prospective randomized trials are required to elucidate the impact of nucleoside analogs on patients’ survival. A nucleoside analog is the treatment of choice for patients who have been previously treated with an alkylating agent.


2020 ◽  
Vol 36 ◽  
pp. 235-243
Author(s):  
Sara Arranz ◽  
Anna Mané ◽  
Dani Bergé ◽  
Clara Monserrat ◽  
Angel cabezas ◽  
...  
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document